Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1064-1073

  de Steenwinkel, Jurriaan E M ^a   van Vianen, Wim ^a   ten Kate, Marian T ^a   Verbrugh, Henri A ^a   van Agtmael, Michiel A ^b   Schiffelers, Raymond M ^c   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Carrier; Drug targeting; Liposome; Mycobacterial infection

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BICLAR; CLARITHROMYCIN; ETHAMBUTOL; LIPOSOME; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TARGETING; FEMALE; LIPOSOMAL DELIVERY; MONOTHERAPY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; TREATMENT DURATION;

AMIKACIN; ANIMALS; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; ETHAMBUTOL; FEMALE; LIPOSOMES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM AVIUM; RIFAMPIN; SPECIFIC PATHOGEN-FREE ORGANISMS; TUBERCULOSIS;

EID: 35448998975     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm341     Document Type: Article

References (54)

1. Dye C, Watt CJ, Bleed DB et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293: 2767-75.
2. World Health Organization. WHO Expert Committee on Leprosy: Seventh report. WHO Tech Rep Ser 1998; 874: 1-43.
3. Barnes P, Blotch AB, Davidson BT et al. Tuberculosis in patients with immunodeficiency virus infection. N Engl J Med 1991; 324 1644-50.
4. Samual R, Bettiker RL, Suh B. AIDS related Qpportunistic infections, going but not gone. Arch Pharm Res 2002; 25: 215-28.
5. Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex. Clin Chest Med 2002; 23: 633-41.
6. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101 130-8.
7. Espinal MA. The global situation of MDR-TB. Tuberculosis 2003; 83: 44-51.
8. Rastogi R, Sultana Y, Ali A et al. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv 2006; 3: 121-8.
9. Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 2004; 10: 3263-74.
10. Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv 2004; 1: 195-201.
11. Gelperina S, Kisich K, Iseman MD et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172: 1487-90.
12. Du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: Current drug delivery approaches. Respir Res 2006; 7: 118-36.
13. Salem II, Flasher DL, Düzgünes N. Liposome-encapsulated antibiotics. Methods Enzymol 2005; 391: 261-91.
14. Bakker-Woudenberg IAJM, Schiffelers RM, Storm G et al. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol 2005; 391: 228-60.
15. Bakker-Woudenberg IAJM. Long-circulating sterically stabilized liposomes as carders of agents for treatment of infection or for imaging infectious foci. Review. Int J Antimicrob Agents 2002; 19: 299-311.
16. Bakker-Woudenberg IAJM, van Vianen W, van Soolingen D et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. Antimicrob Agents Chemother 2005; 49: 2387-98.
17. Lounis N, Ji B, Truffot-Pemot C et al. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimictob Agents Chemother 1995; 39: 608-12.
18. Benson CA, Williams PI, Currier JS et al. A prospective randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: 1234-43.
19. Bakker-Woudenberg IAJM, ten Kate MT, Steame-Cullen LET. et al. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1995; 171: 938-47.
20. Bermudez LE, Nash KA, Petrofsky M et al. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige Mouse model. J Infect Dis 1996; 174: 1218-22.
21. Furney SK, Skinner PS, Farrer T et al. Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. Antimicrob Agents Chemother 1995; 39: 786-9.
22. Dube MP, Sattler FR, Torriani FJ et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 1997; 176: 1225-32.
23. Peloquin CA, Berning SE. Evaluation of the drug interaction between clarithromycin and rifampin. J Infect Dis Pharmacother 1996; 2 19-35.
24. Wallace RJ Jr, Brown BA, Griffith DE et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-Mycobacterium intracellulare infection. J Infect Dis 1995; 171: 747-50.
25. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications. Int J Antimicrob Agents 2003; 13: 155-68.
26. Bakker-Woudenberg IAJM. Liposomes in the treatment of infectious diseases. In: Puisieux F, Couvreur P, Delattre J, Devissaguet J-P et al., eds. Liposomes, New Systems and New Trends in their Application. Paris, France: Editions de Santé, 1995; 373-96.
27. Schiffelers R, Storm G, Bakker-Woudenberg I, Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 2001; 48: 333-44.
28. Bermudez LE. Use of liposome preparation to treat mycobacterial infections. Immunobiol 1994; 191: 578-83.
29. Saito H, Tomioka H. Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1989; 33: 429-33.
30. Gaspar MM, Neves S, Portaels F et al. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. Antimicrob Agents Chemother 2000; 44: 2424-30.
31. Mehta RT. Liposome-encapsulated clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother 1996; 40: 1893-902.
32. Düzgünes N, Perumal VK, Kesavalu L et al. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1404-11.
33. Cynamon MH, Swenson CE, Palmer GS et al. Liposome-encapsulated amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 1179-83.
34. Bermudez LE, Yau-Young AO, Lin J-P et al. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. J Infect Dis 1990; 161: 1262-8.
35. Ehlers S, Bucke W, Leitzke S et al. Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings. Zbl Bakt 1996; 284: 218-31.
36. Leitzke S, Bucke W, Borner K et al. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother 1998; 42: 459-61.
37. Klemens SP, Cynamon MH, Swenson CE et al. Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1990; 34: 967-70.
38. Düzgünes N, Ashtekar DP, Flasher DL et al. Treatment of Mycobacterium avium-itracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: Role of liposome type and duration of treatment. J Infect Dis 1991; 164: 143-51.
39. Tomioka H, Saito H, Sato K et al. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis 1991; 144: 575-9.
40. LeConte P, Le Gallou F, Potel G et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob Agents Chemother 1994; 38: 2695-701.
41. Nightingale SD, Saletan SL, Swenson CE et al. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob Agents Chemother 1993; 37: 1869-72.
42. Wiley EL, Perry A, Nightingale SD et al. Detection of Mycobacterium avium-intracellulare complex in bone marrow specimens of patients with acquired immunodeficiency syndrome. Am J Clin Pathol 1994; 101: 446-51.
43. Petersen EA, Grayson JB, Hersh EM et al. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J Antimicrob Chemother 1996; 38: 819-28.
44. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171-99.
45. Woodle MC, Newman MS, Working PK. Biological properties of sterically stabilized liposomes. In: Lasic D, Martin F, eds. Stealth Liposomes Boca Raton, FL: CRC Press, 1995; 103-18.
46. Bakker-Woudenberg IA, Lokerse AF, ten Kate MT et al. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1993; 168: 164-71.
47. Schiffelers RM, Bakker-Woudenberg IAJM. Innovation in liposomal formulations for antimicrobial therapy. Review. Expert Opin Ther Patents 2003; 13: 1127-40.
48. Schiffelers RM, Bakker-Woudenberg IAJM, Snijders SV et al. Localization of sterically stabilized liposomes in - Klebsiella pneumoniae-infected rat lung tissue: Influence of liposome characteristics. Biochim Biophys Acta 1999; 1421: 329-39.
49. Schiffelers RM, Bakker-Woudenberg IA, Storm G. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: Dependence on circulation kinetics and presence of poly (ethylene)glycol coating. Biochim Biophys Acta 2000; 1468: 253-61.
50. Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res 2001; 18: 780-7.
51. Bakker-Woudenberg IAJM, ten Kate MT, Guo L et al. Improved efficacy of ciprofloxacin administered in polyethyleneglycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 2001; 45: 1487-92.
52. Schiffelers RM, Storm G, ten Kate MT. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to low bacterial susceptibility and impaired host defense. Antimicrob Agents Chemother 2001; 45: 464-70.
53. Schiffelers RM, Storm G, ten Kate MT et al. In vivo synergistic activity of liposome-co-encapsulated gentamicin and ceftazidime. J Pharmacol Exp Ther 2001; 298: 369-75.
54. Gangadharam PRJ, Ashketar DR, Flasher DL et al. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob Agents Chemother 1995; 39: 725-30.